What are the specific prospects for pharmaceutical enterprises to actively layout high-tech and health industries?

[market analysis of China Pharmaceutical network] with the introduction of the national strategy of "healthy China" and the background of people's consumption upgrading, a number of pharmaceutical enterprises, such as Kangmei pharmaceutical, Tongrentang, Yunnan Baiyao, seize the opportunity to lay out the high-tech health industry in advance, and transform and upgrade to the fields of health food, plant extracts, traditional Chinese medicine formula particles, etc So, how about the specific market prospects or promotion space of these three areas? The author makes a brief analysis In terms of the health food industry, there are nearly 3000 manufacturing enterprises with more than 6 million employees and an output value of about 400 billion According to the public data, the total market volume of China's health care products in 2017 was about 240 billion yuan, and the market scale in 2018 was 292.7 billion yuan, an increase of 10.7% According to the industry, with the improvement of people's living standards, the increase of attention to their own health, and the aggravation of the aging population, it is expected that the health market demand in 2019 will continue to expand, and the overall scale of the health care industry will maintain growth In addition, at present, the per capita consumption level of health care products in China is still relatively low compared with Japan and the United States, so there is much room for improvement in the future However, it is worth noting that in recent years, due to false propaganda, the health care industry has fallen into a crisis of trust In this context, the more strict the industry regulation, the phenomenon of "good money expelling bad money" will appear in the market competition, and unqualified pharmaceutical enterprises will be swept out of the stage In addition, survey statistics show that domestic consumers prefer foreign brands when choosing health care products Therefore, under the attractive condition of health products market cake in China, local pharmaceutical companies need to work harder on products to occupy more market share The export prospect of plant extract industry is good In China, the plant extract industry is still a new industry, which is currently in the development stage With the increasingly strong call of "returning to nature" in recent years, the plant extract industry in China is also concerned, the market scale is constantly expanding, and has a strong market development potential According to the public data, the market scale of China's plant extract industry will reach 24.9 billion yuan in 2018, and by 2022, the market scale will exceed 34.1 billion yuan The industry expects that the export of plant extracts in China has a good prospect, and with the support of relevant favorable policies, the industry will maintain a high-speed development trend in the future In recent years, due to the advantages of convenient use, traditional Chinese medicine formula granules circle powder rapidly in China Its growth rate even exceeds that of traditional Chinese medicine pieces, with an annual compound growth rate of nearly 30% According to the industry announcement report, the sales volume of Chinese herbal formula granules will reach 16.5 billion yuan in 2018 The industry as a whole is in the stage of high-speed development, and it is expected that the future market of the industry can be expected   At present, the market of traditional Chinese medicine formula granules in China is in an oligopoly pattern, among which six national pilot enterprises, such as Chinese traditional medicine and HongRi pharmaceutical, occupy most of the market share However, in addition to these six pilot enterprises, the formula granules pilot work in some provinces and cities is being carried out in succession, and with the opening of the industry access policy, the threshold will be raised, and the disordered competition situation will be improved 。 It is expected that enterprises with strong R & D strength and production capacity are expected to make profits and seize the market opportunities The industry forecasts that under the trend of gradually liberalizing the industry, formula granules will partially replace traditional Chinese medicine pieces and proprietary Chinese medicine, and it is expected to achieve an annual compound growth rate of 40% in the next four years, reaching 44 billion yuan in 2020.